The mayor of León, Antonio Silván, and the founder of mAbxience, Hugo Sigman, visited the biotech company’s facilities located in the León Technology Park. They were accompanied during the visit by Lucas Sigman, mAbxience Industrial Director and Luisa Amoedo, director of the mAbxience León Plant. From the city council, the mayor was accompanied by the Councillor of Employment, Economic Promotion and Education, Javier García-Prieto and the Councillor of Finance and Internal Affairs, Agustín Rajoy.
Quality employment and a commitment to Leonese talent
mAbxience León currently employs more than 80 professionals, of which more than 30 are dedicated exclusively to R&D activities. At the end of 2016, the number of employees at the Leonese plant is expected to exceed 100. The multinational company has made a commitment to local talent, and the proof of this is that 80% of the workforce is from León.
It is worth recalling that mAbxience acquired the plant from Genhelix in May 2014 for 11 million Euros. Since then, it has spent an additional 14 million in refurbishing the facilities and adapting them to the needs of the project; an economic effort that has enabled it to convert the plant into a European leader in the field of biosimilars research and development. Throughout this fiscal year, the company plans to invest around 4 million Euros in the Leonese plant.
First biosimilar drug developed 100% in León
As a recent milestone, the company has successfully started production of its first batches of this drug. Towards the end of 2018, mAbxience is scheduled to launch the first biosimilar drug fully developed in the plant located in the León Technology Park on the market.
mAbxience is the first plant in Europe that has implemented Single-Use technology in most of its processes, from thawing the cell banks through to purifying and formulating the final product, including culture seeding and preparing all the necessary mediums and solutions.
To do this, it uses disposable bioreactors, which gives it a double advantage. On the one hand, greater flexibility, which enables the product to be changed in record time and, on the other, it removes the possibility of any cross-contamination throughout this process.
Furthermore, using this technology results in significant savings on the resources consumed during the production processes. It mainly does this by reducing the consumption of water and cleaning agents, which have fallen 80% and 90%, respectively, as they are not necessary to clean the reactors. This reduces the environmental impact of the facilities.
The ‘Biotechnology production plant’ project was co-financed by the European Regional Development Fund and the Junta de Castilla y León [Castilla y León Regional Government], through the Agency for Innovation, Financing, and Business Internationalisation, as part of the Special Interest Incentives grants.
The León plant is one of the main European facilities producing biopharmaceuticals using fully-integrated Single-Use technology. Its facilities occupy an area of 5,500 square metres.